Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/20249
Title: Readressing the rationale of irradiation in Stage I seminoma guidelines: A critical essay.
Authors: Berghen, Charlien;Albersen, Maarten;Blanchard, Pierre;Bossi, Alberto;Briganti, Alberto;Cozzarini, Cesare;Decaestecker, Karel;Fonteyne, Valérie;Haustermans, Karin;Joniau, Steven;Lim Joon, Daryl;Khoo, Vincent;Nguyen, Paul L;Ost, Piet;Villeirs, Geert;Vulsteke, Christof;Zietman, Anthony;De Meerleer, Gert
Affiliation: Department of Radiation Oncology, Leuven University Hospital, Leuven, Belgium
Olivia Newton John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australia
Department of Urology, Leuven University Hospital, Leuven, Belgium
Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France
Department of Urology, San Raffaele Hospital, Milan, Italy
Department of Radiation Oncology, San Raffaele Hospital, Milan, Italy
Department of Urology, Ghent University Hospital, Ghent, Belgium
Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium
Royal Marsden NHS Foundation Trust, London, United Kingdom
Department of Radiation Oncology, Dana-Farber Cancer Institute, Bringham Women's Hospital, Boston, Massachusetts, United States of America
Department of Radiology, Ghent University Hospital, Ghent, Belgium
Department of Oncology, Ghent Maria Middelares Hospital, Ghent, Belgium Department of Molecular Imaging, Pathology, Radiotherapy& Oncology (MIPRO) Center for Oncological Research (CORE), University of Antwerp, Antwerp, Belgium
Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, United States of America
Issue Date: 25-Jan-2019
EDate: 2019-01-25
Citation: BJU international 2019; online first: 25 January
Abstract: Germ cell tumors (GCT), accounting for 95% of malignant testicular tumors, can be divided into two groups: seminoma (SGCT) and non-seminoma (NSGCT). Seminomas typically arise in men in the fourth decade of life, compromising 60% of the GCT. At diagnosis, approximately 75% present with local disease (Stage I); 15% is detected with metastatic regional lymph nodes (Stage II) and 5-10% present with juxtaregional or visceral metastasis (Stage III) . This article is protected by copyright. All rights reserved.
URI: http://ahro.austin.org.au/austinjspui/handle/1/20249
DOI: 10.1111/bju.14686
PubMed URL: 30680874
Type: Journal Article
Review
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.